» Articles » PMID: 23579327

Association of 1H-MR Spectroscopy and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease: Diverging Behavior at Three Different Brain Regions

Overview
Publisher Sage Publications
Specialties Geriatrics
Neurology
Date 2013 Apr 13
PMID 23579327
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In Alzheimer's disease (AD), levels of N-acetylaspartate (NAA) is diminished and choline (Cho) and myo-inositol (mI) are increased. In cerebrospinal fluid (CSF), tau and phosphoylated tau (p-tau181P) is increased and amyloid-β(1-42) (Aβ42) decreased.

Objectives: 1) To compare metabolites of different 1H-MRS voxels and assess its utility to differentiate AD from controls and to examine the relationship to cognition and to CSF markers.

Methods: 17 healthy controls and 19 AD subjects were studied using 1H-MRS. In the AD cases, additional CSF analysis was obtained.

Results: Relative to controls, AD subjects had reduced NAA/Creatine (Cr) levels in hippocampus (42.3% to 26.0%, p < 0.001), posterior cingulate gyrus (10.4% to 0.2%, p = 0.04), and parietal lobe (14.9% to 3.8%, p = 0.002). Further differences of Cho/Cr and mI/Cr in the hippocampus (Cho/Cr: p = 0.04; mI/Cr: p = 0.015) and posterior cingulate (Cho/Cr: p = 0.001; mI/Cr: p = 0.001) were observed. NAA/Cr of the hippocampus yielded the highest sensitivity (94.1%) and specificity (92.3%) to differentiate AD from controls. NAA/Cr was associated with general cognition (hippocampus: R = 0.68, p < 0.001; parietal lobe: R = 0.57, p = 0.001; posterior cingulate: R = 0.50, p = 0.003). Higher hippocampal NAA/Cr was related to higher CSF Aβ42, while lower parietal NAA/Cr was associated with a higher CSF total tau (t-tau) and p-tau181P. Posterior cingulate mI/Cr was related to CSF t-tau and NAA/mI.

Conclusion: 1H-MRS is an appropriate measure in AD. Measurement at different regions presumably reflects different pathological changes.

Citing Articles

Understanding Proton Magnetic Resonance Spectroscopy Neurochemical Changes Using Alzheimer's Disease Biofluid, PET, Postmortem Pathology Biomarkers, and APOE Genotype.

Kara F, Kantarci K Int J Mol Sci. 2024; 25(18).

PMID: 39337551 PMC: 11432594. DOI: 10.3390/ijms251810064.


Magnetic Resonance Spectroscopy (MRS) in Alzheimer's Disease.

Sheikh-Bahaei N, Chen M, Pappas I Methods Mol Biol. 2024; 2785:115-142.

PMID: 38427192 DOI: 10.1007/978-1-0716-3774-6_9.


Neurochemical Ameliorating of the Hippocampus in Dyslipidemic Alzheimer Patients Following Silymarin; a Double-Blind Placebo-Controlled Randomized Clinical Trial.

Rustamzadeh A, Sadigh N, Shabani R, Ahadi R, Vahabi Z, Shabani A Med J Islam Repub Iran. 2024; 37:123.

PMID: 38318412 PMC: 10843210. DOI: 10.47176/mjiri.37.123.


Longitudinal evaluation of proton magnetic resonance spectroscopy metabolites as biomarkers in Huntington's disease.

Lowe A, Rodrigues F, Arridge M, De Vita E, Johnson E, Scahill R Brain Commun. 2022; 4(6):fcac258.

PMID: 36382217 PMC: 9665272. DOI: 10.1093/braincomms/fcac258.


Lower Posterior Cingulate N-Acetylaspartate to Creatine Level in Early Detection of Biologically Defined Alzheimer's Disease.

Chen Q, Abrigo J, Liu W, Han E, Yeung D, Shi L Brain Sci. 2022; 12(6).

PMID: 35741606 PMC: 9220959. DOI: 10.3390/brainsci12060722.